Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11227489rdf:typepubmed:Citationlld:pubmed
pubmed-article:11227489lifeskim:mentionsumls-concept:C1140680lld:lifeskim
pubmed-article:11227489lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:11227489lifeskim:mentionsumls-concept:C0162638lld:lifeskim
pubmed-article:11227489lifeskim:mentionsumls-concept:C0334227lld:lifeskim
pubmed-article:11227489lifeskim:mentionsumls-concept:C0253023lld:lifeskim
pubmed-article:11227489lifeskim:mentionsumls-concept:C0030956lld:lifeskim
pubmed-article:11227489lifeskim:mentionsumls-concept:C1441547lld:lifeskim
pubmed-article:11227489lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:11227489lifeskim:mentionsumls-concept:C0179400lld:lifeskim
pubmed-article:11227489lifeskim:mentionsumls-concept:C1334043lld:lifeskim
pubmed-article:11227489lifeskim:mentionsumls-concept:C2697616lld:lifeskim
pubmed-article:11227489pubmed:issue1lld:pubmed
pubmed-article:11227489pubmed:dateCreated2001-2-28lld:pubmed
pubmed-article:11227489pubmed:abstractTextWe found that a short synthetic peptide corresponding to the "antisense homology box" of Fas ligand induced apoptotic cell death of Fas-expressing human ovarian cancer cell lines. The peptide was deduced from residues 256-265 of human Fas ligand, based on the hypothesis that it should contain a specific binding site to the corresponding Fas. Interestingly, the ovarian cancer cell line NOS4, which was sensitive to anti-Fas antibody induced apoptosis, was not affected by the peptide, whereas another cell line, SKOV-3, which was insensitive to anti-Fas antibody, was killed by the peptide. Thus, this short peptide was shown to have a unique activity to induce apoptosis in human ovarian cancer cells in a manner different from anti-Fas antibody.lld:pubmed
pubmed-article:11227489pubmed:languageenglld:pubmed
pubmed-article:11227489pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11227489pubmed:citationSubsetIMlld:pubmed
pubmed-article:11227489pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11227489pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11227489pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11227489pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11227489pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11227489pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11227489pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11227489pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11227489pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11227489pubmed:statusMEDLINElld:pubmed
pubmed-article:11227489pubmed:monthFeblld:pubmed
pubmed-article:11227489pubmed:issn1360-8185lld:pubmed
pubmed-article:11227489pubmed:authorpubmed-author:SuzukiHHlld:pubmed
pubmed-article:11227489pubmed:authorpubmed-author:NakashimaIIlld:pubmed
pubmed-article:11227489pubmed:authorpubmed-author:YokoyamaIIlld:pubmed
pubmed-article:11227489pubmed:authorpubmed-author:KojimaTTlld:pubmed
pubmed-article:11227489pubmed:authorpubmed-author:HayakawaAAlld:pubmed
pubmed-article:11227489pubmed:authorpubmed-author:TajiriHHlld:pubmed
pubmed-article:11227489pubmed:issnTypePrintlld:pubmed
pubmed-article:11227489pubmed:volume5lld:pubmed
pubmed-article:11227489pubmed:ownerNLMlld:pubmed
pubmed-article:11227489pubmed:authorsCompleteYlld:pubmed
pubmed-article:11227489pubmed:pagination37-41lld:pubmed
pubmed-article:11227489pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11227489pubmed:meshHeadingpubmed-meshheading:11227489...lld:pubmed
pubmed-article:11227489pubmed:meshHeadingpubmed-meshheading:11227489...lld:pubmed
pubmed-article:11227489pubmed:meshHeadingpubmed-meshheading:11227489...lld:pubmed
pubmed-article:11227489pubmed:meshHeadingpubmed-meshheading:11227489...lld:pubmed
pubmed-article:11227489pubmed:meshHeadingpubmed-meshheading:11227489...lld:pubmed
pubmed-article:11227489pubmed:meshHeadingpubmed-meshheading:11227489...lld:pubmed
pubmed-article:11227489pubmed:meshHeadingpubmed-meshheading:11227489...lld:pubmed
pubmed-article:11227489pubmed:meshHeadingpubmed-meshheading:11227489...lld:pubmed
pubmed-article:11227489pubmed:meshHeadingpubmed-meshheading:11227489...lld:pubmed
pubmed-article:11227489pubmed:meshHeadingpubmed-meshheading:11227489...lld:pubmed
pubmed-article:11227489pubmed:meshHeadingpubmed-meshheading:11227489...lld:pubmed
pubmed-article:11227489pubmed:meshHeadingpubmed-meshheading:11227489...lld:pubmed
pubmed-article:11227489pubmed:meshHeadingpubmed-meshheading:11227489...lld:pubmed
pubmed-article:11227489pubmed:meshHeadingpubmed-meshheading:11227489...lld:pubmed
pubmed-article:11227489pubmed:year2000lld:pubmed
pubmed-article:11227489pubmed:articleTitleA short peptide derived from the antisense homology box of Fas ligand induces apoptosis in anti-Fas antibody-insensitive human ovarian cancer cells.lld:pubmed
pubmed-article:11227489pubmed:affiliationDepartment of Equipment for Research and Education, Nagoya University, School of Medicine, Japan.lld:pubmed
pubmed-article:11227489pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11227489pubmed:publicationTypeComparative Studylld:pubmed